Compare Ascendis Pharma A/S (ASND) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bitwise Crypto Industry Innovators ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bitwise Crypto Industry Innovators ETF trades at $23.64. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BITQ | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Crypto-linked |
52-Week High | $277.18 | $30.43 |
52-Week Low | $163.32 | $16.74 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BITQ is trading at $23.93, down 0.91% on the day, with technical indicators showing a bearish trend across moving averages and oscillators. The stock faces resistance at $24 and support at $23. Recent news highlights investor concerns about cryptocurrency exposure through ETFs, though some analysts see potential in crypto industry innovators during market recoveries.
The outlook remains cautious due to weak technical momentum and sector volatility. Investment opportunity exists for those betting on long-term crypto industry growth, but risks include regulatory uncertainty and market sentiment swings. Current levels near support may attract contrarian buyers if broader crypto markets stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
